Fructus aurantii immaturus or Fructus aurantii total flavone extract extracted by water decoction, and use thereof

Abstract

The present invention relates to an immature bitter orange total flavone extract or a submature bitter orange total flavone extract. The preparation method for the extract comprises that: immature bitter orange or submature bitter orange is adopted, and cut into decoction pieces or crushed; water is added, wherein the amount of the water is 4-15 times the amount of the cut decoction pieces; a decoction treatment is performed three times, wherein each decoction extraction time is 1-3 hours; the resulting decocted solutions are mixed, and then filtered; the resulting filtrate passes through the treated non-polar macroporous resin; impurities are removed by elution sequentially with water and ethanol, wherein the concentration of the ethanol is less than 20%; then 25-90% ethanol and 0.5-2% sodium hydroxide are adopted to carry out elution; the resulting eluent from the ethanol elution treatment is collected, and is subjected to a reduced pressure condense treatment until the relative density of the obtained fluid extract is 1.20-1.40 (50-70 DEG C); the obtained fluid extract is subjected to treatments of reduced pressure drying and crushing to obtain the immature bitter orange total flavone extract or the submature bitter orange total flavone extract, wherein the drying temperature is 60-80 DEG C. The extract can be adopted for preparation of drugs for treatments of gastrointestinal motility dysfunction type functional dyspepsia, epigastric pain, abdominal distension, anorexia, eructation, nausea and vomiting caused by chemotherapeutic drugs or other reasons, and can be prepared into the pharmaceutically acceptable formulation.

Description

technical field [0001] The invention relates to a decocted and extracted total flavonoid extract of Fructus Aurantii or Fructus Fructus Fructus and its application. Background technique [0002] Functional dyspepsia (FD) is a common and frequently-occurring disease. Also known as gastric insufficiency, or gastric motility disorder. Is a common clinical syndrome, foreign statistics show that 1 / 3 of the population suffered from FD, accounting for 20% to 30% of outpatients. Domestically, it accounts for about 50% of digestive system outpatients, and occurs in 20% to 40% of normal people. In addition, more than 80% of cancer patients will cause vomiting after chemotherapy. The main anti-vomiting drugs are Metoclon and Zofran, but chemical drugs are accompanied by fatigue, dizziness, headache, and even neck and back muscle pain. Cramp symptoms. [0003] At present, Western medicine mainly treats modinline, cisapride, mosapride, etc.; however, with the extensive use of them,...

AI Technical Summary

Problems solved by technology

However, Citrus aurantium and Fructus aurantium are only used in a small amount in clinical formulas and Chinese patent medicine preparations, and a large amount of resources have not been widely used. Their natural effects of breaking Qi and eliminating stagnation may not be fully exploited in the similarity with modern gastric motility-promoting drugs.

Images